{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T06:47:40Z","timestamp":1792478860930,"version":"4.5.0"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,12,7]],"date-time":"2023-12-07T00:00:00Z","timestamp":1701907200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,12,7]],"date-time":"2023-12-07T00:00:00Z","timestamp":1701907200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003710","name":"Korea Health Industry Development Institute","doi-asserted-by":"publisher","award":["HI20C0865"],"award-info":[{"award-number":["HI20C0865"]}],"id":[{"id":"10.13039\/501100003710","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Complement Med Ther"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Yukgunja-tang (YGJ) is an herbal prescription used to treat the symptoms of gastroesophageal reflux disease (GERD). Although many preclinical and clinical studies on YGJ have been conducted on GERD, there is a lack of evidence from blinded studies to exclude placebo effects. Therefore, this protocol proposes a clinical trial that is single-centered, randomized, double-blinded, double-dummy to objectively evaluate the efficacy and safety of co-administered YGJ and rabeprazole (RPZ) in patients with GERD previously treated with proton pump inhibitors (PPIs) and still experiencing symptoms.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A total of 86 participants with refractory GERD (rGERD) will be randomized in a 1:1 ratio to the treatment [YGJ and RPZ (10\u00a0mg\/d)] and control groups [double-dose RPZ (20\u00a0mg\/d)] for 4\u00a0weeks of treatment (weeks 0\u20134) followed by 4\u00a0weeks of follow-up (weeks 4\u20138). The Frequency Scale for the Symptoms of GERD will be analyzed for the primary endpoint. Reflux Disease Questionnaire, Reflux Symptom Score, GERD-Health Related Quality of Life, Overall Treatment Evaluation, Spleen Qi Deficiency Questionnaire, Damum Questionnaire, and dyspepsia Visual Analogue Scale will be used to evaluate treatment effects on GERD related symptoms and quality of life and to compare treatment effects by subgroups. Safety tests will be analyzed by investigating adverse events.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Discussion<\/jats:title>\n                <jats:p>This clinical trial will be the first rigorous double-blind, double-dummy, placebo-controlled study to precisely evaluate the efficacy and safety of the combination of YGJ and PPIs in the treatment of rGERD. The results of this study will provide a reliable clinical basis for selecting botanical drug treatments for patients with rGERD.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration<\/jats:title>\n                <jats:p>Clinical Research Information Service (registration number: KCT0008600, July 13, 2023, <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/cris.nih.go.kr\">https:\/\/cris.nih.go.kr<\/jats:ext-link>).<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12906-023-04283-3","type":"journal-article","created":{"date-parts":[[2023,12,7]],"date-time":"2023-12-07T15:02:22Z","timestamp":1701961342000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Clinical efficacy of Yukgunja-tang combined with a proton pump inhibitor for refractory gastroesophageal reflux disease: study protocol for randomized, double-blind, double-dummy clinical trial"],"prefix":"10.1186","volume":"23","author":[{"given":"Na-Yeon","family":"Ha","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jung-Wook","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinsung","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,12,7]]},"reference":[{"issue":"8","key":"4283_CR1","doi-asserted-by":"publisher","first-page":"1900","DOI":"10.1111\/j.1572-0241.2006.00630.x","volume":"101","author":"N Vakil","year":"2006","unstructured":"Vakil N, Van Zanten SV, Kahrilas P, et al. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. Am J Gastroenterol. 2006;101(8):1900\u201320.","journal-title":"Am J Gastroenterol"},{"issue":"1","key":"4283_CR2","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/S0889-8553(05)70366-6","volume":"25","author":"JE Richter","year":"1996","unstructured":"Richter JE. Typical and atypical presentations of gastroesophageal reflux disease: the role of esophageal testing in diagnosis and management. Gastroenterol Clin North Am. 1996;25(1):75\u2013102.","journal-title":"Gastroenterol Clin North Am"},{"issue":"22","key":"4283_CR3","doi-asserted-by":"publisher","first-page":"2340","DOI":"10.1056\/NEJMoa054391","volume":"354","author":"BC Jacobson","year":"2006","unstructured":"Jacobson BC, Somers SC, Fuchs CS, et al. Body-mass index and symptoms of gastroesophageal reflux in women. N Engl J Med. 2006;354(22):2340\u20138.","journal-title":"N Engl J Med"},{"issue":"2","key":"4283_CR4","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1038\/ajg.2008.150","volume":"104","author":"MA Kwiatek","year":"2009","unstructured":"Kwiatek MA, Mirza F, Kahrilas PJ, et al. Hyperdynamic upper esophageal sphincter pressure: a manometric observation in patients reporting globus sensation. Am J Gastroenterol. 2009;104(2):289.","journal-title":"Am J Gastroenterol"},{"issue":"2","key":"4283_CR5","doi-asserted-by":"publisher","first-page":"70","DOI":"10.3904\/kjm.2022.97.2.70","volume":"97","author":"HK Jung","year":"2022","unstructured":"Jung HK, Tae CH, Song KH, et al. 2020 Seoul consensus on the diagnosis and management of gastroesophageal reflux disease. Korean J Intern Med. 2022;97(2):70\u201392.","journal-title":"Korean J Intern Med"},{"issue":"6","key":"4283_CR6","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1136\/gutjnl-2012-304269","volume":"63","author":"HB El-Serag","year":"2014","unstructured":"El-Serag HB, Sweet S, Winchester CC, et al. Update on the epidemiology of gastro-oesophageal reflux disease: a systematic review. Gut. 2014;63(6):871\u201380.","journal-title":"Gut"},{"issue":"2","key":"4283_CR7","first-page":"367","volume":"7","author":"SY Lee","year":"2001","unstructured":"Lee SY. Biopsychosocial understanding and quality of life in gastroesophageal reflux disease. Kor J Neurogastroenterol Motil. 2001;7(2):367\u201374.","journal-title":"Kor J Neurogastroenterol Motil"},{"issue":"3","key":"4283_CR8","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/S0002-9343(97)00354-9","volume":"104","author":"M Wood","year":"1998","unstructured":"Wood M, Maton PN, Sorensen S. The impact of gastroesophageal reflux disease on health-related quality of life. Am J Med. 1998;104(3):252\u20138.","journal-title":"Am J Med"},{"issue":"8","key":"4283_CR9","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1016\/S1542-3565(04)00288-5","volume":"2","author":"BB Dean","year":"2004","unstructured":"Dean BB, Gano AD Jr, Knight K, et al. Effectiveness of proton pump inhibitors in nonerosive reflux disease. Clin Gastroenterol Hepatol. 2004;2(8):656\u201364.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"17","key":"4283_CR10","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1056\/NEJM199510263331703","volume":"333","author":"S Vigneri","year":"1995","unstructured":"Vigneri S, Termini R, Leandro G, et al. A comparison of five maintenance therapies for reflux esophagitis. N Engl J Med. 1995;333(17):1106\u201310.","journal-title":"N Engl J Med"},{"issue":"9","key":"4283_CR11","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1136\/gutjnl-2011-301897","volume":"61","author":"D Sifrim","year":"2012","unstructured":"Sifrim D, Zerbib F. Diagnosis and management of patients with reflux symptoms refractory to proton pump inhibitors. Gut. 2012;61(9):1340\u201354.","journal-title":"Gut"},{"issue":"6","key":"4283_CR12","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1097\/MCG.0000000000000854","volume":"51","author":"R Hunt","year":"2017","unstructured":"Hunt R, Armstrong D, Katelaris P, et al. World gastroenterology organisation global guidelines: GERD global perspective on gastroesophageal reflux disease. J Clin Gastroenterol. 2017;51(6):467\u201378.","journal-title":"J Clin Gastroenterol"},{"issue":"2","key":"4283_CR13","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1001\/jamainternmed.2015.7927","volume":"176","author":"AJ Schoenfeld","year":"2016","unstructured":"Schoenfeld AJ, Grady D. Adverse effects associated with proton pump inhibitors. JAMA Intern Med. 2016;176(2):172\u20134.","journal-title":"JAMA Intern Med"},{"issue":"4","key":"4283_CR14","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1053\/j.gastro.2017.01.031","volume":"152","author":"DE Freedberg","year":"2017","unstructured":"Freedberg DE, Kim LS, Yang YX. The risks and benefits of long-term use of proton pump inhibitors: expert review and best practice advice from the American Gastroenterological Association. Gastroenterology. 2017;152(4):706\u201315.","journal-title":"Gastroenterology"},{"issue":"1","key":"4283_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/00000441-200401000-00001","volume":"327","author":"DC Buckles","year":"2004","unstructured":"Buckles DC, Sarosiek I, McCallum RW, et al. Delayed gastric emptying in gastroesophageal reflux disease: reassessment with new methods and symptomatic correlations. Am J Med Sci. 2004;327(1):1\u20134.","journal-title":"Am J Med Sci"},{"issue":"9","key":"4283_CR16","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1111\/nmo.12611","volume":"27","author":"T Herregods","year":"2015","unstructured":"Herregods T, Bredenoord A, Smout A. Pathophysiology of gastroesophageal reflux disease: new understanding in a new era. Neurogastroenterol Motil. 2015;27(9):1202\u201313.","journal-title":"Neurogastroenterol Motil"},{"issue":"2","key":"4283_CR17","doi-asserted-by":"publisher","first-page":"165","DOI":"10.5056\/jnm20161","volume":"27","author":"CW Huh","year":"2021","unstructured":"Huh CW, Lee SK, Park JC, et al. A systematic review and meta-analysis of randomized control trials: combination treatment with proton pump inhibitor plus prokinetic for gastroesophageal reflux disease. J Neurogastroenterol Motil. 2021;27(2):165.","journal-title":"J Neurogastroenterol Motil"},{"key":"4283_CR18","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1046\/j.1365-2036.1999.00022.x","volume":"13","author":"H Ishizaki","year":"1999","unstructured":"Ishizaki H. Cytochrome P450 and the metabolism of proton pump inhibitors\u2014emphasis on rabeprazole. Aliment Pharmacol Ther. 1999;13:27\u201336.","journal-title":"Aliment Pharmacol Ther"},{"key":"4283_CR19","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.1023\/A:1018802908358","volume":"42","author":"LP Leite","year":"1997","unstructured":"Leite LP, Johnston BT, Barrett J, et al. Ineffective esophageal motility (IEM)(the primary finding in patients with nonspecific esophageal motility disorder). Dig Dis Sci. 1997;42:1859\u201365.","journal-title":"Dig Dis Sci"},{"key":"4283_CR20","doi-asserted-by":"publisher","first-page":"884","DOI":"10.3389\/fphar.2020.00884","volume":"11","author":"YK Dai","year":"2020","unstructured":"Dai YK, Wu YB, Wen H, et al. Different traditional herbal medicines for the treatment of gastroesophageal reflux disease in adults. Front Pharmacol. 2020;11:884.","journal-title":"Front Pharmacol."},{"issue":"1","key":"4283_CR21","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/0300-9629(95)02061-6","volume":"113","author":"Y Goso","year":"1996","unstructured":"Goso Y, Ogata Y, Ishihara K, et al. Effects of traditional herbal medicine on gastric mucin against ethanol-induced gastric injury in rats. Comp Biochem Physiol C Toxicol Pharmacol. 1996;113(1):17\u201321.","journal-title":"Comp Biochem Physiol C Toxicol Pharmacol"},{"issue":"7","key":"4283_CR22","doi-asserted-by":"publisher","first-page":"2004","DOI":"10.1053\/j.gastro.2008.02.078","volume":"134","author":"H Takeda","year":"2008","unstructured":"Takeda H, Sadakane C, Hattori T, et al. Rikkunshito, an herbal medicine, suppresses cisplatin-induced anorexia in rats via 5-HT2 receptor antagonism. Gastroenterology. 2008;134(7):2004\u201313.","journal-title":"Gastroenterology"},{"issue":"4","key":"4283_CR23","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1111\/j.1365-2036.1993.tb00120.x","volume":"7","author":"M Tatsuta","year":"1993","unstructured":"Tatsuta M, Iishi H. Effect of treatment with Liu-Jun\u2010Zi\u2010Tang (TJ\u201043) on gastric emptying and gastrointestinal symptoms in dyspeptic patients. Aliment Pharmacol Ther. 1993;7(4):459\u201362.","journal-title":"Aliment Pharmacol Ther"},{"key":"4283_CR24","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1007\/s00535-011-0488-5","volume":"47","author":"K Tominaga","year":"2012","unstructured":"Tominaga K, Iwakiri R, Fujimoto K, et al. Rikkunshito improves symptoms in PPI-refractory GERD patients: a prospective, randomized, multicenter trial in Japan. J Gastroenterol. 2012;47:284\u201392.","journal-title":"J Gastroenterol"},{"key":"4283_CR25","doi-asserted-by":"publisher","first-page":"248481","DOI":"10.1093\/ecam\/nep173","volume":"2011","author":"K Tominaga","year":"2011","unstructured":"Tominaga K, Kido T, Ochi M, et al. The traditional japanese medicine rikkunshito promotes gastric emptying via the antagonistic action of the 5-HT 3 receptor pathway in rats. Evid Based Complement Alternat Med. 2011;2011:248481.","journal-title":"Evid Based Complement Alternat Med"},{"key":"4283_CR26","doi-asserted-by":"publisher","first-page":"8546357","DOI":"10.1155\/2018\/8546357","volume":"2018","author":"SJ Ko","year":"2018","unstructured":"Ko SJ, Park JW, Lee JH, et al. An herbal medicine, yukgunja-tang is more effective in a type of functional dyspepsia categorized by facial shape diagnosis: a placebo-controlled, double-blind, randomized trial. Evid Based Complement Alternat Med. 2018;2018:8546357.","journal-title":"Evid Based Complement Alternat Med"},{"key":"4283_CR27","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1007\/s00383-014-3565-z","volume":"30","author":"H Kawahara","year":"2014","unstructured":"Kawahara H, Tazuke Y, Soh H, et al. Physiological analysis of the effects of rikkunshito on acid and non-acid gastroesophageal reflux using pH-multichannel intraluminal impedance monitoring. Pediatr Surg Int. 2014;30:927\u201331.","journal-title":"Pediatr Surg Int"},{"key":"4283_CR28","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1007\/s00383-009-2453-4","volume":"25","author":"H Kawahara","year":"2009","unstructured":"Kawahara H, Mitani Y, Nomura M, et al. Impact of rikkunshito, an herbal medicine, on delayed gastric emptying in profoundly handicapped patients. Pediatr Surg Int. 2009;25:987\u201390.","journal-title":"Pediatr Surg Int"},{"issue":"1","key":"4283_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-230X-14-116","volume":"14","author":"Y Sakata","year":"2014","unstructured":"Sakata Y, Tominaga K, Kato M, et al. Clinical characteristics of elderly patients with proton pump inhibitor-refractory non-erosive reflux disease from the G-PRIDE study who responded to rikkunshito. BMC Gastroenterol. 2014;14(1):1\u201310.","journal-title":"BMC Gastroenterol"},{"issue":"4","key":"4283_CR30","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1111\/j.1365-2982.2010.01648.x","volume":"23","author":"M Shiratori","year":"2011","unstructured":"Shiratori M, Shoji T, Kanazawa M, et al. Effect of rikkunshito on gastric sensorimotor function under distention. Neurogastroenterol Motil. 2011;23(4):323-e156.","journal-title":"Neurogastroenterol Motil"},{"issue":"31","key":"4283_CR31","doi-asserted-by":"publisher","first-page":"5118","DOI":"10.3748\/wjg.v19.i31.5118","volume":"19","author":"R Tokashiki","year":"2013","unstructured":"Tokashiki R, Okamoto I, Funato N, et al. Rikkunshito improves globus sensation in patients with proton-pump inhibitor-refractory laryngopharyngeal reflux. World J Gastroenterol. 2013;19(31):5118.","journal-title":"World J Gastroenterol"},{"key":"4283_CR32","doi-asserted-by":"publisher","first-page":"1392","DOI":"10.1007\/s00535-013-0896-9","volume":"49","author":"K Tominaga","year":"2014","unstructured":"Tominaga K, Kato M, Takeda H, et al. A randomized, placebo-controlled, double-blind clinical trial of rikkunshito for patients with non-erosive reflux disease refractory to proton-pump inhibitor: the G-PRIDE study. J Gastroenterol. 2014;49:1392\u2013405.","journal-title":"J Gastroenterol"},{"key":"4283_CR33","doi-asserted-by":"publisher","first-page":"e7586","DOI":"10.1136\/bmj.e7586","volume":"346","author":"AW Chan","year":"2013","unstructured":"Chan AW, Tetzlaff JM, G\u00f8tzsche PC, et al. SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials. BMJ. 2013;346:e7586.","journal-title":"BMJ"},{"issue":"2","key":"4283_CR34","doi-asserted-by":"publisher","first-page":"100","DOI":"10.4103\/0976-500X.72352","volume":"1","author":"KF Schulz","year":"2010","unstructured":"Schulz KF, Altman DG, Moher D. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. J Pharmacol Pharmacother. 2010;1(2):100\u20137.","journal-title":"J Pharmacol Pharmacother"},{"issue":"1","key":"4283_CR35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.22246\/jikm.2022.43.1.1","volume":"43","author":"YJ Cho","year":"2022","unstructured":"Cho YJ, Ha NY, Ko SJ, et al. A study of the reliability and validity of standard tools for the pattern identification of gastroesophageal reflux disease. J Int Korean Med. 2022;43(1):1\u201321.","journal-title":"J Int Korean Med"},{"key":"4283_CR36","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1007\/s00535-004-1417-7","volume":"39","author":"M Kusano","year":"2004","unstructured":"Kusano M, Shimoyama Y, Sugimoto S, et al. Development and evaluation of FSSG: frequency scale for the symptoms of GERD. J Gastroenterol. 2004;39:888\u201391.","journal-title":"J Gastroenterol"},{"key":"4283_CR37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1477-7525-6-31","volume":"6","author":"M Shaw","year":"2008","unstructured":"Shaw M, Dent J, Beebe T, et al. The Reflux Disease Questionnaire: a measure for assessment of treatment response in clinical trials. Health Qual Life Outcomes. 2008;6:1\u20136.","journal-title":"Health Qual Life Outcomes"},{"key":"4283_CR38","doi-asserted-by":"crossref","unstructured":"Min HK, Jeon SY, Lechien JR, et al. Translation and validation of the Korean Version of the Reflux Symptom score. J Voice. 2021:S0892-1997(21)00306-4.","DOI":"10.1016\/j.jvoice.2021.08.026"},{"issue":"2","key":"4283_CR39","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1111\/j.1442-2050.2007.00658.x","volume":"20","author":"V Velanovich","year":"2007","unstructured":"Velanovich V. The development of the GERD-HRQL symptom severity instrument. Dis Esophagus. 2007;20(2):130\u20134.","journal-title":"Dis Esophagus"},{"issue":"1","key":"4283_CR40","doi-asserted-by":"publisher","first-page":"157","DOI":"10.13048\/jkm.14015","volume":"35","author":"HW Oh","year":"2014","unstructured":"Oh HW, Lee JW, Kim JS, et al. Study on the development of a standard instrument of diagnosis and assessment for spleen deficiency pattern. J Korean Med. 2014;35(1):157\u201370.","journal-title":"J Korean Med"},{"issue":"1","key":"4283_CR41","first-page":"64","volume":"10","author":"JS Park","year":"2006","unstructured":"Park JS, Yang DH, Kim MY, et al. Development of questionnaire for Damum patternization. J Soc Korean Med Diag. 2006;10(1):64\u201377.","journal-title":"J Soc Korean Med Diag"},{"key":"4283_CR42","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1007\/s00535-010-0342-1","volume":"46","author":"M Hongo","year":"2011","unstructured":"Hongo M, Miwa H, Kusano M, et al. Effect of rabeprazole treatment on health-related quality of life and symptoms in patients with reflux esophagitis: a prospective multicenter observational study in Japan. J Gastroenterol. 2011;46:297\u2013304.","journal-title":"J Gastroenterol"},{"issue":"2","key":"4283_CR43","doi-asserted-by":"publisher","first-page":"281","DOI":"10.5056\/jnm19050","volume":"26","author":"S Park","year":"2020","unstructured":"Park S, Kwon JW, Park JM, et al. Treatment pattern and economic burden of refractory gastroesophageal reflux disease patients in Korea. J Neurogastroenterol Motil. 2020;26(2):281.","journal-title":"J Neurogastroenterol Motil"},{"key":"4283_CR44","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.2165\/00003495-200767110-00001","volume":"67","author":"R Fass","year":"2007","unstructured":"Fass R. Proton-pump inhibitor therapy in patients with gastro-oesophageal reflux disease: putative mechanisms of failure. Drugs. 2007;67:1521\u201330.","journal-title":"Drugs"},{"issue":"6","key":"4283_CR45","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1111\/j.1365-2036.2010.04406.x","volume":"32","author":"H El-Serag","year":"2010","unstructured":"El-Serag H, Becher A, Jones R. Systematic review: persistent reflux symptoms on proton pump inhibitor therapy in primary care and community studies. Aliment Pharmacol Ther. 2010;32(6):720\u201337.","journal-title":"Aliment Pharmacol Ther"},{"issue":"5","key":"4283_CR46","first-page":"211","volume":"25","author":"T Hayakawa","year":"1999","unstructured":"Hayakawa T, Arakawa T, Kase Y, et al. Liu-Jun-Zi-Tang, a kampo medicine, promotes adaptive relaxation in isolated guinea pig stomachs. Drugs Exp Clin Res. 1999;25(5):211\u20138.","journal-title":"Drugs Exp Clin Res"},{"key":"4283_CR47","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1007\/s00383-007-1986-7","volume":"23","author":"H Kawahara","year":"2007","unstructured":"Kawahara H, Kubota A, Hasegawa T, et al. Effects of Rikkunshito on the clinical symptoms and esophageal acid exposure in children with symptomatic gastroesophageal reflux. Pediatr Surg Int. 2007;23:1001\u20135.","journal-title":"Pediatr Surg Int"},{"issue":"2","key":"4283_CR48","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1254\/jphs.FPJ04056X","volume":"98","author":"T Kido","year":"2005","unstructured":"Kido T, Nakai Y, Kase Y, et al. Effects of Rikkunshi-to, a traditional Japanese medicine, on the delay of gastric emptying induced by NG-nitro-L-arginine. J Pharmacol Sci. 2005;98(2):161\u20137.","journal-title":"J Pharmacol Sci"},{"key":"4283_CR49","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3389\/fphar.2015.00007","volume":"6","author":"K Tominaga","year":"2015","unstructured":"Tominaga K, Arakawa T. Clinical application of kampo medicine (rikkunshito) for common and\/or intractable symptoms of the gastrointestinal tract. Front Pharmacol. 2015;6:7.","journal-title":"Front Pharmacol"},{"issue":"1","key":"4283_CR50","doi-asserted-by":"publisher","first-page":"69","DOI":"10.5056\/jnm14078","volume":"21","author":"SE Kim","year":"2015","unstructured":"Kim SE, Kim N, Oh S, et al. Predictive factors of response to proton pump inhibitors in Korean patients with gastroesophageal reflux disease. J Neurogastroenterol Motil. 2015;21(1):69.","journal-title":"J Neurogastroenterol Motil"},{"issue":"12","key":"4283_CR51","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1001\/archinte.160.12.1810","volume":"160","author":"JE Richter","year":"2000","unstructured":"Richter JE, Peura D, Benjamin SB, et al. Efficacy of omeprazole for the treatment of symptomatic acid reflux disease without esophagitis. Arch Intern Med. 2000;160(12):1810\u20136.","journal-title":"Arch Intern Med"}],"container-title":["BMC Complementary Medicine and Therapies"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12906-023-04283-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12906-023-04283-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12906-023-04283-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,7]],"date-time":"2023-12-07T16:02:15Z","timestamp":1701964935000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccomplementalternmed.biomedcentral.com\/articles\/10.1186\/s12906-023-04283-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,7]]},"references-count":51,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["4283"],"URL":"https:\/\/doi.org\/10.1186\/s12906-023-04283-3","relation":{},"ISSN":["2662-7671"],"issn-type":[{"value":"2662-7671","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,7]]},"assertion":[{"value":"24 October 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 November 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 December 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The clinical trial protocol was approved by the IRB of Kyung Hee University Korean Medicine Hospital (IRB File No.: 2020\u201305-007, June 3, 2020). The study protocol was registered with the Clinical Research Information Service (CRIS) (Version 2.1, registration number: KCT0008600). Any amendments to a previously completed protocol will be resubmitted, approved, and documented in the IRB and CRIS. Based on the ethical principles and relevant regulations of the Declaration of Helsinki, a detailed explanation of the clinical trial process will be provided to the participants by the PI and authorized researchers in accordance with legal procedures. The participants will be required to sign an informed consent form of their own free will before participating in the clinical trial.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"444"}}